NURVAQAY

Registered
Word Mark

Key Information

Serial Number

Registration Number

Status

Registered

Ownership

GG

Owner Name

Type: Organization / Private Company Limited by Shares

Address

GSK Medicines Research Centre, Gunnels Wood Road
Stevenage, SG12NY
United Kingdom

Critical Dates

First Use Date

Not filed yet

Filing Date

Sep 3, 2025

Registration Date

Feb 10, 2026

Mark Descriptions

Goods

Class 5
Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological...

Mark Elements

Text Mark
NURVAQAY
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO website

Trademark Timeline

Filing Date

Sep 3, 2025

Publication Date

Dec 23, 2025

Registration Date

Feb 10, 2026

USPTO Records

TitleDateCategorySourcePagesFormatActions

AI AssessmentCached Mar 12, 2026, 12:11 PM
Cached

AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.

Trademark Summary

NURVAQAY is a standard character mark covering pharmaceuticals in Class 005, including preparations for treating damaged skin and tissue, pain, inflammation, obesity, infectious diseases, and various conditions such as viral, metabolic, cardiovascular, oncological, and immune system disorders, along with vaccines and anti-infectives; it spans additional classes 006, 018, 044, 046, 051, and 052. The mark is owned by Glaxo Group Limited, a UK private company limited by shares based at GSK Medicines Research Centre in Stevenage, UK. It is currently registered on the Principal Register, with registration number 8137357 issued on February 10, 2026, claiming priority from a UK registration (UK00004253150) filed and registered on August 22, 2025.

Recent Activity

Filed on September 3, 2025, the application faced a suspension inquiry in October 2025, to which applicant responded in November, leading to approval for publication on November 25, 2025. It was published for opposition on December 23, 2025, with no oppositions filed, and registered on February 10, 2026.
USPTO
AI Analysis
v2.8.0
Generated Mar 12, 2026, 12:11 PM

Never miss important updates for this trademark

Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach

Cookie Preferences

We use cookies (including Google Analytics) to improve our site and understand how visitors use it.